Research Study on How People With Type 2 Diabetes Tolerate Switching From Semaglutide to Cagrisema

NCT07817251 · Not yet recruiting

Last updated 2026-09-22

This study is testing how well people with type 2 diabetes tolerate switching from the medication semaglutide to a new combination treatment called cagrisema.

Status Not yet recruiting Approved but enrollment has not started.

Phase Phase 3 Confirms effectiveness in a large group before approval.

Type Interventional (clinical trial)

Design Randomized, quadruple-blind treatment study

Participants 210 people Planned (estimated).

Who can join Ages 18+ · all sexes

Timeline Started 2026-09 · est. completion 2027-07

Where 40 sites · United States

What this study is testing ClinicalTrials.gov NCT07817251 ↗

Description as written by the study sponsor.

The purpose of this clinical study is to look at the safety and tolerability of switching from semaglutide to CagriSema, for participants who have type 2 diabetes. All participants will get CagriSema, the treatment being tested. Participants will be in this clinical study for about 6 months.

Treatments tested

CagriSema Drug

CagriSema will be administered s.c. once weekly.

Main thing measured	Number of treatment emergent adverse events (TEAEs)
Sponsor	Novo Nordisk A/S
Conditions studied	Diabetes Mellitus, Type 2
GLP-1 drugs	semaglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT07817251 ↗